- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/755 - Factors VIII
Patent holdings for IPC class C07K 14/755
Total number of patents in this class: 847
10-year publication summary
|
72
|
57
|
74
|
56
|
50
|
50
|
45
|
39
|
41
|
9
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bioverativ Therapeutics Inc. | 215 |
89 |
| Takeda Pharmaceutical Company Limited | 2722 |
58 |
| Octapharma AG | 203 |
28 |
| Novo Nordisk A/S | 2287 |
21 |
| The Children's Hospital of Philadelphia | 832 |
20 |
| CSL Behring GmbH | 352 |
15 |
| CSL Limited | 251 |
15 |
| St. Jude Children's Research Hospital | 240 |
15 |
| CSL Behring Lengnau AG | 125 |
15 |
| The Trustees of the University of Pennsylvania | 4396 |
14 |
| Baxalta Incorporated | 300 |
14 |
| Bayer HealthCare LLC | 1323 |
13 |
| Baxalta GmbH | 104 |
13 |
| Emory University | 1691 |
12 |
| Baxter International Inc. | 2199 |
11 |
| BioMarin Pharmaceutical Inc. | 386 |
11 |
| UCL Business Ltd | 642 |
11 |
| Baxter Healthcare S.A. | 1651 |
10 |
| Georgia Tech Research Corporation | 2889 |
10 |
| Spark Therapeutics, Inc. | 174 |
9 |
| Other owners | 443 |